Part 3/9:
Both hosts expressed curiosity regarding Icahn's actual plans. Traditionally an activist investor, Icahn's lack of detailed strategy in this case raised questions about whether he intended to push for drastic changes or simply to lock in value.
The Coming Cash Windfall
A crucial factor in Icahn's investment is Allergan’s potential $40.5 billion sale of its generics unit to Teva Pharmaceuticals. Harjes speculated that if this deal goes through, Allergan could end up with a substantial amount of cash, which Icahn would likely want to leverage for shareholder return, possibly via dividends or share buybacks.